All In Biotech

Drug Trial Radar · NCT03396445

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Feb 18, 2018

Primary completion

Sep 27, 2024

Study completion Sep 27, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 11, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults. Boserolimab monotherapy or boserolimab plus pembrolizumab combination therapy will be administered in adults with advanced solid tumors, including endometrial cancer, for up to 35 administrations (approximately 2 years). The safety and pharmacokinetics of boserolimab when administered with pembrolizumab, pemetrexed and carboplatin in adults with non-squamous non-small cell lung cancer (NSCLC) and boserolimab when administered with pembrolizumab and nab-paclitaxel in adults with triple-negative breast cancer (TNBC) will also be assessed.

Conditions

  • Pharmacokinetics
  • Solid Tumor
  • Carcinoma, Non-Small-Cell Lung
  • Triple Negative Breast Neoplasms

Interventions

  • BoserolimabDrug

    IV infusion

  • PembrolizumabBiological

    IV infusion

  • PemetrexedDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • Nab-paclitaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days in Cycle 1
  2. Number of Participants With One or More AEsTime frame: Up to approximately 78 months
  3. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to 23 months

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • University of South Alabama, Mitchell Cancer Institute ( Site 0020)

    Mobile, Alabama

  • Florida Cancer Specialists ( Site 0002)

    Sarasota, Florida

  • The West Clinic, P.C. ( Site 0021)

    Germantown, Tennessee

  • FALP-UIDO ( Site 0502)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 0501)

    Santiago, Region M. de Santiago, Chile

  • Soroka Medical Center-Oncology ( Site 0012)

    Beersheba, Israel

  • Hadassah Ein Kerem Medical Center ( Site 0010)

    Jerusalem, Israel

  • The Chaim Sheba Medical Center - Oncology Institute ( Site 0001)

    Ramat Gan, Israel

  • Antoni van Leeuwenhoek Ziekenhuis ( Site 0003)

    Amsterdam, North Holland, Netherlands

  • Erasmus MC ( Site 0031)

    Rotterdam, South Holland, Netherlands

  • Seoul National University Hospital-Internal Medicine ( Site 0702)

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 0701)

    Seoul, South Korea

  • Instituto Catalan de Oncologia - ICO ( Site 0044)

    Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz ( Site 0041)

    Madrid, Spain

  • Centro Integral Oncologico Clara Campal START Madrid ( Site 0040)

    Madrid, Spain

  • Hospital Universitario Quiron Madrid ( Site 0043)

    Pozuelo de Alarcón, Madrid, Spain

  • National Taiwan University Hospital-Oncology ( Site 0801)

    Taipei, Taiwan

  • Koo Foundation Sun Yat-Sen Cancer Center ( Site 0802)

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.